NCT03931785

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study of MD-7246 Administered Orally for 12 Weeks to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 515 (actual)
• Sponsor: Ironwood Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Conditions

• Irritable Bowel Syndrome With Diarrhea (IBS-D)

Interventions

Type	Name	Description
DRUG	MD-7246	Oral tablet
DRUG	Placebo	Matching oral tablet

Timeline

• Start date: 2019-05-01
• Primary completion: 2020-02-26
• Completion: 2020-03-11
• First posted: 2019-04-30
• Last updated: 2021-03-12
• Results posted: 2021-03-12

Locations

80 sites across 1 country: United States

Regulatory

• FDA-regulated drug study